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BRIEF COMMUNICATION
FIRST ISOLATION OF DENGUE 3 IN BRAZIL FROM AN IMPORTED CASE
Iray Maria ROCCO(1), Berenice Bustamanti KAVAKAMA(2) & Cecília Luiza Simões SANTOS(3)
SUMMARY
The authors report the isolation of dengue 3 virus for the first time in Brazil. The patient, resident in Limeira-SP, traveled to
Nicaragua on May 16th, 1998, where he stayed for two months. Starting on August 14 th he had fever, headache, myalgia, arthralgia,
retro-orbital pain and diarrhea. He returned to Brazil on August 16th and was hospitalized in the next day. The patient had full recovery
and was discharged on August 20th. The virus was isolated in C6/36 cell culture inoculated with serum collected on the 6th day after
the onset of the symptoms. The serotype 3 was identified by indirect immunofluorescence assays performed with type-specific
monoclonal antibodies. This serotype was further confirmed by polymerase chain reaction analysis. The introduction of a new dengue
serotype in a susceptible population is a real threat for the occurrence of severe forms of the disease. The isolation and identification
of dengue virus are important in order to monitoring the serotypes circulating in Brazil and to take the measures necessary to prevent
and control an epidemic.
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Dengue, a mosquito-born virus infection, is considered one of the
most important and widespread reemerging infectious diseases in
developing countries. Clinically, the infection can be asymptomatic or it
can manifest as an undifferentiated febrile illness, known as dengue fever
(DF) characterized by “flu-like” symptoms including fever, headaches
and myalgia. Major complications are known as dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS), with occurrence of
plasma leakage and trombocytopenia, leading to death in a significant
number of cases3.
Dengue is caused by dengue virus, a positive-stranded RNA virus
of the family Flaviviridae. It is transmitted to humans by Aedes sp
mosquitoes and are divided into four closely related but antigenically
distinct serotypes from 1 to 4. Infection by one serotype does not protect
the individual against infection by a second serotype of dengue virus6.
Instead, the appearance of clinically severe infections such as DHF and
DSS seems to be mostly related to subsequent infections by a virus of
different serotype from that of former infection. The mechanisms involved
in the pathogenesis of dengue infections remain unresolved.
Epidemiological studies have shown a higher incidence of DHF/DSS in
secondary infection compared with the primary one, supporting the
antibody-dependent enhancement hypothesis5. On the other hand,
variation in virulence among viral strains may account for severe dengue
disease in confirmed cases of primary infection10. At present, in spite of
many studies all over the world, no dengue vaccine is available and the
prevention of infection depends mainly on mosquito vector control.
In Brazil, millions of dengue infections have been notified all over
the country since 1986. In the State of São Paulo outbreaks of DF have
been notified since 1987, when the first autochtonous cases by serotype
1 virus were detected. Dengue 2 virus was introduced in 1996 and
nowadays both serotypes are present in many regions of the State, as in
other States of the country2,9.
In 1998, dengue serotype 3 was isolated in our laboratory from an
imported case. The patient, a 46-year-old male, living in Limeira, traveled
on May 16th to Nicaragua, where he stayed for three months. Starting on
August 14th he had fever, headaches, myalgia, arthralgia, retro-orbital
pains and diarrhea. He arrived in Brazil on August 16th and was
hospitalized in the next day. He had full recovery and was discharged on
August 20th.
The virus isolation was accomplished in C6/36 cell culture inoculated
with serum collected on the 6th day after the onset of disease symptoms.
Indirect immunofluorescence assays performed with type-specific
monoclonal antibodies, showed positive reaction for dengue 3 virus4.
This serotype identification was further confirmed by polymerase chain
reaction (PCR) analysis. Virus RNA isolated from infected cell culture
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supernatant by silica method1, was reverse-transcribed and amplified
with oligonucleotide concensus primers developed by LANCIOTTI et
al.7 The second-round of PCR, performed with type-specific primers,
detected DNA products of 290 bp, characteristic of dengue virus serotype
3 (Fig. 1).
Dengue 3 was introduced in Nicaragua in 1994 causing a large
epidemic by DF/DSS and in the following year it spread to other Central
America countries and Mexico. Molecular analysis showed that this virus
was genetically distinct from that one which circulated 16 years before
in the Americas, but it presented the same genotype as the one isolated
in the epidemic that has caused major epidemics of DHF in Sri Lanka
and India8.
The introduction of a new dengue serotype in a susceptible population
is a real threat for the occurrence of severe forms of the disease, whatever
the mechanism of pathogenesis involved. That is the case of our country,
where there is a great number of people who have already contracted
dengue infection by serotype 1 or 2.
The isolation and characterization of dengue 3 virus in our laboratory
show the necessity of constant monitoring of dengue virus serotypes
circulating in our country in order to alert the health authorities of any
relevant changes observed so that measures to prevent and control a new
epidemic are taken.
RESUMO
Primeiro isolamento de dengue 3 no Brasil de um caso importado
Os autores relatam o isolamento do vírus dengue 3 pela primeira
vez no Brasil. O paciente, residente em Limeira-SP, viajou em 16 de
maio de 1998 para a Nicarágua, onde permaneceu por três meses. A
partir de 14 de agosto, ele apresentou febre, dor de cabeça, mialgia,
artralgia, dor retro-orbital e diarréia. Ele retornou ao Brasil em 16 de
agosto e foi hospitalizado no dia seguinte. O paciente teve completa
recuperação, recebendo alta em 20 de agosto. O vírus foi isolado em
cultura de células C6/36 inoculadas com soro colhido no 60 dia após o
início dos sintomas. O sorotipo 3 foi identificado por imunofluorescência
indireta com anticorpos monoclonais tipo-específico. O sorotipo foi
posteriormente confirmado por PCR. A introdução de um novo sorotipo
de dengue em uma população susceptível é uma ameaça para a ocorrência
de formas severas da doença. O isolamento e a identificação do vírus
dengue são de grande importância a fim de monitorar a introdução de
novos sorotipos e para que medidas sejam tomadas para prevenir e
controlar novas epidemias.
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Fig. 1 - Identification of dengue 3 serotype by reverse-transcriptase-polymerase chain reaction.
Ethidium bromide stained agarose gel showing: molecular markers (A), the amplified product
corresponding to 290bp obtained with dengue 3 specific primers set (Lanciotti, 1992) (B)
and negative control (C).
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